ClinicalTrials.gg
Not yet recruitingNCT07078955Updated Oct 20, 2025

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

A Phase 2 interventional study of BRM421 Ophthalmic Solution, 0.03% and Artificial Tear in Dry Eye Disease (DED) and Keratoconjunctivitis Sicca, sponsored by BRIM Biotechnology Inc.. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.

Primary conditionKeratoconjunctivitis SiccaRegistry: Dry Eye SyndromesReclassifiedWhy we changed it
Registry
Dry Eye Syndromes — the first condition term the registry derived for this study.
ClinicalTrials.gg
Keratoconjunctivitis Sicca
Why
  1. The study's listed conditions name Keratoconjunctivitis Sicca, a narrower term within Dry Eye Syndromes.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BRIM Biotechnology Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)

02

Conditions studied

  • Dry Eye Disease (DED)
  • Keratoconjunctivitis Sicca

Browse trials for

03

In context

Keratoconjunctivitis Sicca Reclassified

85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.

This study's planned enrollment of 99 is above the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.

Browse Keratoconjunctivitis Sicca studies →

Lead sponsor

BRIM Biotechnology Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Compared within Keratoconjunctivitis Sicca, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dry Eye Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ≥18 years of age;
  • Are willing and able to comply with all study procedures and restrictions and the visit schedule;
  • Have a self-reported history of dry eye prior to enrollment;
  • If a woman of (WOCBP): are non-lactating, have a negative urine pregnancy test (UPT), and agree to use an acceptable form of for the duration of the study;

Exclusion criteria

Exclusion Criteria:

  • Within 3 months prior to Visit 1, have participated in any other study or used an investigational product or device;
  • Have any history of organ or bone marrow transplant, immunodeficiency disorder, , or , or any evidence of acute active hepatitis A (anti-hepatitis A virus immunoglobulin M);
  • Have any significant illness or condition that, in the opinion of the Investigator, could affect the study outcome measures. Such illnesses include (but are not limited to) Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, severe cardiopulmonary disease, poorly controlled hypertension or diabetes, or drug/alcohol addiction;
  • Within 12 months prior to Visit 1, have undergone any ocular surgical procedure, including laser-assisted in situ keratomileusis (LASIK) or a similar corneal refractive surgery;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Other
    Artificial Tear

    Drug: Artificial Tear

  • Active comparator
    BRM421 Ophthalmic Solution, 0.03%

    Drug: BRM421 Ophthalmic Solution, 0.03%

  • Active comparator
    BRM421 Ophthalmic Solution, 0.06%

    Drug: BRM421 Ophthalmic Solution, 0.06%

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in total corneal fluorescein staining (tCFS) score

    Total corneal fluorescein staining (tCFS) score by using NEI Scale (0-20, higher scores mean a worse outcome)

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Nov 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 22, 2025
StartEst.
Dec 2025
Primary completionEst.
Nov 2026
CompletionEst.
Mar 2027
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07078955
Lead sponsor
BRIM Biotechnology Inc.
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Dec 2025 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 20, 2025

Study contacts

Ning Alin Associate Director
Contact
alin.ning@brimbiotech.com
+886-2-26598586

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fulipiftide · Lubricant Eye Drops

Start the discussion